NS Partners Ltd Raises Stake in Johnson & Johnson (JNJ)
NS Partners Ltd raised its position in Johnson & Johnson (NYSE:JNJ) by 70.3% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 82,247 shares of the company’s stock after buying an additional 33,962 shares during the period. Johnson & Johnson accounts for about 1.5% of NS Partners Ltd’s portfolio, making the stock its 18th largest position. NS Partners Ltd’s holdings in Johnson & Johnson were worth $10,244,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of JNJ. Lau Associates LLC boosted its stake in shares of Johnson & Johnson by 12.8% in the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock worth $5,839,000 after buying an additional 5,335 shares during the last quarter. Loomis Sayles & Co. L P boosted its stake in shares of Johnson & Johnson by 396.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 110,823 shares of the company’s stock worth $12,768,000 after buying an additional 88,510 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Johnson & Johnson by 7.3% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock worth $1,627,000 after buying an additional 957 shares during the last quarter. Burke & Herbert Bank & Trust Co. boosted its stake in shares of Johnson & Johnson by 2.6% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after buying an additional 1,218 shares during the last quarter. Finally, Independent Advisor Alliance acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $4,035,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.
Johnson & Johnson (NYSE JNJ) traded up 0.01% during midday trading on Friday, reaching $133.10. 4,270,571 shares of the company’s stock were exchanged. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The stock has a market cap of $357.24 billion, a P/E ratio of 22.52 and a beta of 0.78. The firm’s 50-day moving average is $133.09 and its 200 day moving average is $126.30.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.74 earnings per share. Equities analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.
JNJ has been the subject of a number of research reports. Morgan Stanley raised their target price on shares of Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, July 5th. BidaskClub cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 1st. Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.54 target price for the company. in a report on Monday, May 1st. Jefferies Group LLC restated a “hold” rating and set a $140.00 target price on shares of Johnson & Johnson in a report on Friday, June 16th. Finally, Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $133.72.
In other news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.